Ruxolitinib in Operable Head and Neck Cancer

Phase 2 Terminated 16 enrolled University of California, San Francisco Incyte Corporation · collab

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to assess the safety and efficacy of ruxolitinib in patients with operable Head and neck squamous cell carcinoma (HNSCC) who are planned for definitive surgery.

Timeline

Start: 2018-06-08
Primary completion: 2023-10-18
Completion: 2023-10-18

Outcome

Outcome not reported

Stopped (Enrollment): “Low accrual”

Publications

Background Qureshy Z, Li H, Zeng Y, Rivera J, Cheng N, Peterson CN, Kim MO, Ryan WR, Ha PK, Bauman JE, Wang SJ, Long SR, Johnson DE, Grandis JR. STAT3 Activation as a Predictive Biomarker for Ruxolitinib Response in Head and Neck Cancer. Clin Cancer Res. 2022 Nov 1;28(21):4737-4746. doi: 10.1158/1078-0432.CCR-22-0744.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Ruxolitinib	Small molecule	15 mg	Oral
Subject	Ruxolitinib	Small molecule	20 mg	Oral